Intravesical instillation of bacillus Calmette-Guerin (BCG) is the treatment of choice for non-muscle-invasive @entity150 (NMIBC) of high grade and/or @entity189 in situ. This study evaluated the feasibility, efficacy, and tolerance of BCG instillations in eight kidney recipients for end-stage aristolochic acid @entity8 (AAN), a condition at high risk of @entity189 , and diagnosed for NMIBC. Five of them had relapsed after mitomycin C treatment. Tolerance to BCG was evaluated clinically and regular follow-up with fluorescence cystoscopy was performed along with renal graft function monitoring. Immunosuppression doses were adjusted and prophylactic anti-tuberculous treatment given to reduce risks of graft rejection and infection. After a mean follow-up period of 50  months, seven of the eight @entity1 are free of relapse and kidney graft function remained unchanged. Tolerance was good, except for one episode of @entity221 and one early discontinuation because of subjective discomfort. No @entity281 was observed. This is the first clinical observation of successful BCG therapy for NMIBC in @entity1 given transplant for end-stage AAN. Under standardized conditions, immunotherapy based on intravesical BCG is feasible, effective, and well tolerated in renal transplantation.

Bacillus Calmette-Guerin therapy in non-muscle-invasive XXXX after renal transplantation for end-stage aristolochic acid @entity8 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy'] @entity189 :: ('MESH:D002277', 'Disease') :: ['urothelial carcinoma', 'carcinoma'] @entity281 :: ('MESH:D007239', 'Disease') :: ['systemic tuberculous infection'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer'] @entity221 :: ('MESH:D005334', 'Disease') :: ['fever']
@entity150 :: (MESH:D001749,Disease) :: ['bladder carcinoma']
